Femasys reports pricing of $8.0M underwritten offering

Femasys reports pricing of $8.0M underwritten offering

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator in the fertility and non-surgical permanent birth control space, has announced an $8.0 million underwritten offering. The proceeds from this offering will be used to support the commercialization of the company's innovative fertility solutions, including the recently launched FemSperm Setup Kit.

The FemSperm Setup Kit is designed to enable gynecologists to perform FemaSeed Intratubal Insemination in their offices, a significant advancement in the company's fertility platform. The kit includes specialized components such as a pre-configured centrifuge for optimizing sperm preparation, addressing a key technical barrier that previously limited the adoption of FemaSeed among gynecologists.

FemaSeed, a next-generation artificial insemination solution, has demonstrated more than double the pregnancy rates compared to traditional intrauterine insemination (IUI) in cases of low male sperm count. The treatment is currently authorized in multiple markets, including the U.S., Europe, UK, Canada, Israel, Australia, and New Zealand. By expanding access to FemaSeed through gynecology practices, Femasys aims to position the treatment as a first-line fertility option ahead of more invasive and expensive procedures like IVF.

The underwritten offering is a strategic move for Femasys, aligning with its broader commercialization strategy to create an ecosystem of products around the core FemaSeed platform. The company has outlined plans to introduce a family of products designed to fully activate gynecologists and expand the use of FemaSeed.

The announcement follows the company's recent launch of the FemSperm Setup Kit, which includes customized components such as a pre-configured centrifuge to optimize sperm preparation for use with FemaSeed. By providing a streamlined, in-office solution, Femasys is establishing the foundation for gynecologist-driven adoption of FemaSeed as a first-step fertility treatment, expanding patient access to alternatives ahead of IVF and advancing the Company’s commercialization strategy.

Femasys has also reported that the company's CEO, Kathy Lee-Sepsick, emphasized the importance of this strategic step in strengthening the company's commercialization pathway by bringing FemaSeed into the hands of the physicians who see patients first, opening new access points for women seeking fertility care and positioning Femasys for scalable revenue growth.

The underwritten offering is expected to provide Femasys with the financial resources needed to further develop and commercialize its innovative fertility solutions, including the FemSperm Setup Kit and other products in the pipeline. The company's focus on creating an ecosystem of products around the core FemaSeed platform suggests a razor-and-blade business model that could drive recurring revenue if successfully implemented.

References:

[1] Femasys Inc. (2025). Femasys Announces $8.0M Underwritten Offering. Retrieved from https://www.stocktitan.net/news/FEMY/femasys-announces-fem-sperm-tm-kit-to-activate-gynecologists-and-x7erf0kl21im.html